Investor Presentaiton

SUN PHARMA Western Europe & Other Markets # 8% API & Others Sun Pharma today US Formulations 5th largest generics company in US* with one of the largest ANDAs pipeline (154 ANDAs awaiting approval) Presence in generics, Specialty and branded segments with more than 440 approved products FY15 sales: US$ 2,244 mn (2) India 25% International 75% Geographical sales split Market cap: US$ 33 bn (1) India Branded Generics No.1 ranked with 13 classes of doctor categories Leading position in high growth chronic therapies ⚫ Specializes in technically complex products FY15 sales: US$ 1,099 mn (2) Gross Sales: US$ 4,510 mn (2) EBITDA: US$ 1,295 (29% margin) (2) R&D Investment: 7.2% of Net Sales Globalized supply chain 55% owned by promoter group Strong balance sheet, low debt Strong product pipeline Revenue Break-up Emerging Markets 14% India Branded Generics 24% US Formulation 50% 4% Note: Emerging Markets Presence in over 100 countries across Africa, Americas, Asia and Eastern & Central Europe Key focus markets - Brazil, Mexico, Russia, Romania, South Africa, and complementary & affiliated markets FY15 sales: US$ 611 mn (2) (1) As of October, 31, 2015 using spot exchange rate of INR/USD = 65.22. (2) Using average exchange rate for FY15 of INR/USD = 61.13 # Includes Western Europe, Canada, Australia & New Zealand, Japan and other markets. All sales numbers in US$ for 12 months ended March 31, 2015. * Source: Evaluate Pharma for 12 months ended Dec 2014 © Sun Pharmaceutical Industries Limited. All Rights Reserved. Western Europe, Canada, ANZ & others Presence across majority of markets in Western Europe, Canada and A&NZ Product portfolio includes differentiated offerings for hospitals, injectables and generics for retail market FY15 sales: US$ 381 mn (2) 160

View entire presentation